[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Kazakh Eye Research Institute\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":96},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,54,77],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100637250","full-thickness-macular-hole-surgery-a-comparison-of-ten-techniques-100637250",false,"NCT07606404","Full-Thickness Macular Hole Surgery: A Comparison of Ten Techniques","Vitreoretinal Surgery for Full-Thickness Macular Hole: A Comparative Study of Ten Techniques","FTMH-10","Inclusion Criteria:\n\nAdults aged ≥18 years.\n\nFull-thickness macular hole (FTMH) eligible for pars plana vitrectomy (PPV).\n\nSymptom duration ≤12 months.\n\nClear ocular media sufficient for high-quality OCT imaging.\n\nNo prior pars plana vitrectomy in the study eye.\n\nNo severe foveal atrophy on OCT.\n\nAble and willing to comply with postoperative positioning and follow-up visits.\n\nWritten informed consent provided.\n\nExclusion Criteria:\n\nA. Etiology-Related \u002F Secondary Macular Holes:\n\nTraumatic macular hole.\n\nHigh myopia with posterior staphyloma (axial length \\>28 mm and\u002For spherical equivalent ≤-8.0 D).\n\nDiabetic tractional retinal detachment (TRD) or significant tractional maculopathy.\n\nRetinal vascular occlusion-related macular hole.\n\nUveitis-related macular hole.\n\nAdvanced age-related macular degeneration (AMD) with foveal atrophy.\n\nB. Prior Interventions:\n\nAny prior pars plana vitrectomy in the study eye.\n\nC. Ocular Conditions That May Affect Outcomes or Safety:\n\nActive or recent ocular infection or inflammation (e.g., uveitis, endophthalmitis, keratitis).\n\nUncontrolled glaucoma (intraocular pressure \\>28 mmHg despite treatment).\n\nMedia opacity precluding adequate OCT (e.g., dense cataract or corneal opacity).\n\nGeographic atrophy involving the fovea.","ALL","18 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study compares ten modern vitreoretinal surgical techniques for full-thickness macular hole repair. Participants will be randomly assigned to one of the surgical approaches during pars plana vitrectomy, using stratified randomization based on macular hole size to ensure balanced groups. The main goal is to determine which technique provides the highest anatomical closure rate on optical coherence tomography (OCT) and the best visual outcomes. Follow-up visits are scheduled at Day 7, Month 1, and Year 1 after surgery to assess OCT findings, visual acuity, safety outcomes, and the need for reoperation.",[27],"Macular Holes",[29,30,31,32,33,34,35,36,37,38,39,40],"Full-Thickness Macular Hole","Pars Plana Vitrectomy","Internal Limiting Membrane Peeling","Inverted ILM Flap","ILM Flap","Optical Coherence Tomography","Macular Hole Closure","Best-Corrected Visual Acuity","Platelet-Rich Plasma","Amniotic Membrane Graft","Macular Hydrodissection","Surgical Technique","RECRUITING","2026-05-29",{"date":44,"type":45},"2026-06-02","ACTUAL",{"date":47,"type":45},"2026-05-25",{"date":49,"type":21},"2028-05-27",{"name":51,"class":52},"Kazakh Eye Research Institute","NETWORK",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":22,"phases":64,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":74,"leadSponsor":76,"locationsCount":53},"100640503","tear-interleukin-biomarkers-after-glaucoma-treatment-100640503","NCT07592988","Tear Interleukin Biomarkers After Glaucoma Treatment","Tear Fluid Interleukin Biomarkers and Intraocular Pressure Response After Micropulse Transscleral Cyclophotocoagulation, Conventional Cyclophotocoagulation, and Antiglaucoma Surgery in Patients With Glaucoma","TIGT","Inclusion Criteria:\n\n* Decision to treat by MP-CPC Laser\n* Patients diagnosed with Glaucoma\n* Patients aged 18 years old and above\n* Glaucoma that is inadequately controlled on medical therapy\n\nExclusion Criteria:\n\n* Patients age less than 18 years\n* Patients unable or unwilling to provide informed consent to participate in the study\n* Patients potentially unavailable for follow up visits\n* Patients with significant scleral thinning\n* Patients with ocular infection, inflammation or intraocular surgery in the study eye 2 months prior to enrollment in the study\n* Albino patients that have no iris pigmentation",{"count":63,"type":21},24,[24],"This prospective study aims to evaluate inflammatory biomarkers in tear fluid in patients with glaucoma undergoing micropulse transscleral cyclophotocoagulation (MP-CPC), continuous-wave cyclophotocoagulation (CPC), and antiglaucoma surgeries. The study will assess the concentrations of pro- and anti-inflammatory interleukins in tear samples collected before treatment, 5-7 days after the procedure, and 1 month postoperatively.\n\nIntraocular pressure (IOP) will be measured at the same time points. The correlation between changes in interleukin levels and IOP reduction will be analyzed. Additionally, the study aims to compare inflammatory response patterns among the MP-CPC, CPC, and surgical treatment groups and to identify interleukin profiles associated with a clinically significant hypotensive effect.",[67],"Glaucoma",[67,69],"Micropulse Laser","2026-05-12",{"date":72,"type":45},"2026-05-18",{"date":72,"type":21},{"date":75,"type":21},"2026-08-18",{"name":51,"class":52},{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":87,"conditions":88,"keywords":89,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":92,"startDateStruct":93,"completionDateStruct":94,"leadSponsor":95,"locationsCount":53},"100638029","morphometric-markers-of-the-effectiveness-of-micropulse-cyclophotocoagulation-100638029","NCT07592923","Morphometric Markers of the Effectiveness of Micropulse Cyclophotocoagulation","Morphometric Markers of the Effectiveness of Micropulse Cyclophotocoagulation: The Influence of Choroidal Thickness on the Extent and Duration of the Hypotensive Effect","MMEMC",{"count":85,"type":21},20,[24],"This prospective study aims to evaluate morphometric markers of treatment response following micropulse transscleral cyclophotocoagulation (MP-CPC) in patients with glaucoma. The study will assess changes in choroidal thickness and the choroidal vascularity index (CVI) measured by optical coherence tomography (OCT) before treatment, 3-7 days after the procedure, and 1 month postoperatively.\n\nIntraocular pressure (IOP) will be measured at the same time points. The correlation between changes in choroidal thickness, the choroidal vascularity index (CVI) and IOP reduction will be analyzed. Additionally, the study seeks to determine the minimal baseline choroidal thickness associated with a clinically significant hypotensive effect after MP-CPC.",[67],[90,91],"micropulse laser","glaucoma",{"date":72,"type":45},{"date":72,"type":21},{"date":75,"type":21},{"name":51,"class":52},""]